Morgan Stanley Pro Phase Labs, Inc. Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
A detailed history of Morgan Stanley transactions in Pro Phase Labs, Inc. stock. As of the latest transaction made, Morgan Stanley holds 9,166 shares of PRPH stock, worth $4,216. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,166
Previous 4,382
109.17%
Holding current value
$4,216
Previous $10,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding PRPH
# of Institutions
30Shares Held
2.38MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA655KShares$301,3140.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny286KShares$131,7830.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL237KShares$108,9190.0% of portfolio
-
Sheets Smith Wealth Management208KShares$95,8180.02% of portfolio
-
Geode Capital Management, LLC Boston, MA204KShares$93,6220.0% of portfolio
About ProPhase Labs, Inc.
- Ticker PRPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 16,024,400
- Market Cap $7.37M
- Description
- ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Lege...